- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Piper Sandler reiterates Overweight rating on Upstream Bio stock | 1 | Investing.com | ||
| 14.10. | Truist Securities initiates Upstream Bio stock with Buy rating on respiratory drug potential | 2 | Investing.com | ||
| 14.10. | Upstream Bio: Truist Securities startet Coverage mit Kaufempfehlung dank Potenzial bei Atemwegsmedikament | 1 | Investing.com Deutsch | ||
| 30.09. | Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug's Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress | 291 | GlobeNewswire (Europe) | - Data show verekitug prevents TSLP binding to the TSLP receptor by occupying ligand binding sites - - Additionally, findings show that verekitug outcompetes TSLP in the presence of preformed heterodimeric... ► Artikel lesen | |
| 09.09. | Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum | 1 | GlobeNewswire (USA) | ||
| 02.09. | Upstream Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.09. | Upstream Bio Reports Positive Top-line Results From Phase 2 VIBRANT Study | 7 | RTTNews | ||
| UPSTREAM BIO Aktie jetzt für 0€ handeln | |||||
| 26.08. | Piper Sandler reiterates Overweight rating on Upstream Bio stock | 2 | Investing.com | ||
| 06.08. | Upstream Bio, Inc. reports Q2 results | 1 | Seeking Alpha | ||
| 06.08. | Upstream Bio, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 06.08. | Upstream Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 28.07. | JPMorgan reiterates Overweight rating on Upstream Bio stock ahead of trial data | 2 | Investing.com | ||
| 08.07. | Upstream Bio startet Phase-2-Studie für COPD-Medikament Verekitug | 1 | Investing.com Deutsch | ||
| 08.07. | Upstream Bio begins phase 2 COPD trial for verekitug | 1 | Investing.com | ||
| 08.07. | Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD) | 246 | GlobeNewswire (Europe) | - Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD - - Broadens global development program for... ► Artikel lesen | |
| 15.06. | Upstream Bio: Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor | 3 | GlobeNewswire (USA) | ||
| 05.06. | Upstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 | 1 | GlobeNewswire (USA) | ||
| 20.05. | Upstream Bio Appoints Stacy Price As CTO | 1 | RTTNews | ||
| 20.05. | Upstream Bio names new chief technology officer | 1 | Investing.com | ||
| 20.05. | Upstream Bio Appoints Stacy Price as Chief Technology Officer | 145 | GlobeNewswire (Europe) | WALTHAM, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory... ► Artikel lesen |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 42,065 | -0,10 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
| RANI THERAPEUTICS | 2,580 | -10,42 % | Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 ... | Rani will receive $10 million upfront payment and is eligible to receive up to $75 million in technology transfer and development milestones, up to $100 million in sales milestones and single digit... ► Artikel lesen | |
| EVOTEC | 6,726 | -1,41 % | Übernahme von Vidac Pharma und Evotec? 400 Mrd. USD bei Pfizer, Merck und Co im Feuer! | Alarm bei Big Pharma! Donald Trump scheint bei der Reduzierung von Medikamentenpreisen ernst zu machen. Gleichzeitig laufen Patente bei Blockbustern aus und ein 400 Mrd. USD Umsatzausfall droht. Pfizer... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 10,010 | -56,76 % | Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis Program | ARCT-032 generally safe and well tolerated
Meaningful trends of clinical activity observed via high resolution CT scans
After only 28 days of treatment with ARCT-032 (10 mg), 4 out of 6 Class... ► Artikel lesen | |
| BIONTECH | 90,60 | -1,79 % | Übernahmefieber und KI-Chance: BioNTech, Novo Nordisk, PanGenomic Health Aktie | Übernahmefieber im Pharma- und Biotech-Bereich. Novo Nordisk hat nach der angekündigten Milliardenübernahme in den USA den nächsten Deal gemeldet. Die Dänen sehen ein mögliches Best-in-Class-Therapeutikum... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,665 | -7,28 % | Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings | ||
| NURIX THERAPEUTICS | 10,540 | +1,05 % | Nurix Therapeutics, Inc.: Nurix Initiates DAYBreak Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia | 600 mg once daily bexobrutideg oral dose cleared by global regulators for pivotal monotherapy trials in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Phase 2 DAYBreak trial initiated... ► Artikel lesen | |
| COGENT BIOSCIENCES | 14,420 | -9,08 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib | Detailed results from bezuclastinib's positive SUMMIT trial evaluating bezuclastinib in patients with NonAdvanced Systemic Mastocytosis planned for presentation at upcoming scientific conference this... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 18,865 | +0,45 % | Summit Therapeutics: Daten überzeugen - BioNTech beobachten! | Am morgigen Dienstag neigt sich die Jahrestagung der European Society for Medical Oncology (ESMO) in Berlin schon wieder dem Ende entgegen. Zahlreiche Unternehmen haben bereits am Wochenende frische... ► Artikel lesen | |
| TEMPUS AI | 71,00 | -7,79 % | AKTIONÄR-Tipp Tempus AI lässt Biotech-Aktie explodieren | Der Megatrend Künstliche Intelligenz (KI) ist an den Börsen weiter in aller Munde. Einer der großen Gewinner der Entwicklung: Tempus AI. Das Unternehmen will mit seinen KI-gestützten Lösungen die Präzisionsmedizin... ► Artikel lesen | |
| SANA BIOTECHNOLOGY | 5,300 | -7,02 % | Sana Biotech surges as Eric Jackson calls it a 100-bagger | ||
| DISC MEDICINE | 87,88 | +2,01 % | Disc Medicine Inc: Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones | Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025, and subsequently was awarded the FDA Commissioner's National... ► Artikel lesen | |
| JANUX THERAPEUTICS | 25,750 | -4,10 % | Janux Therapeutics: Günstige Gelegenheit | Janux Therapeutics hat mit seiner innovativen Plattformtechnologie im letzten Jahr das Interesse vieler Investoren geweckt - nicht zuletzt aufgrund von Übernahmegerüchten. Doch unabhängig von einem... ► Artikel lesen | |
| LENZ THERAPEUTICS | 31,800 | -5,10 % | LENZ Therapeutics, Inc.: LENZ Therapeutics Announces Commercial Product Availability of VIZZ in the United States | VIZZ sample distribution initiated nationwide to Eye Care Professionals Commercial product shipments to be initiated in October to consumers with broad product availability by mid-Q4 2025 VIZZ is... ► Artikel lesen | |
| BEAM THERAPEUTICS | 27,675 | -7,41 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen |
Das Unternehmen UPSTREAM BIO INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 22,125 Euro und damit -0,96 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu UPSTREAM BIO INC finden Sie auf Wallstreet Online.